China NT Pharma Group Company Limited EBIT

China NT Pharma Group Company Limited (1011.HK) currently reports a EBIT of $-26M as of June 2026. That compares with $13M in the prior-year period — down 295.1% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore China NT Pharma Group Company Limited's EBIT history and peer comparisons.

China NT Pharma Group Company Limited's EBIT decreased from $13M to $-26M — a 295.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China NT Pharma Group Company Limited's EBIT of $-26M is lower than the Healthcare sector average of $130B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China NT Pharma Group Company Limited reported $-26M in EBIT as of June 2026. That compares with $13M in the prior-year period — down 295.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-26M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for China NT Pharma Group Company Limited, and consider following 1011.HK for alerts when major investors trade the stock.